Introduction {#s1}
============

The construction of specific plasmid DNA sequences is a routine technique in molecular biology laboratories [@pone.0023685-Sambrook1]. The most widely used DNA sequences (for instance, a promoter followed by a fluorescent protein, a multiple cloning site and a polyadenylation signal) are easily found in commercially-available plasmids [@pone.0023685-Clontech1], [@pone.0023685-Ward1]. However, when requirements start to become more stringent, multiple plasmid modifications are required and, although many changes may be relatively simple to perform, multiple modifications may become time-consuming cloning challenges.

Complex, multi-factor plasmids have to be built frequently for the applications of synthetic biology [@pone.0023685-Shetty1], [@pone.0023685-Tigges1], [@pone.0023685-Basu1], often with the combinatorial use of different DNA parts [@pone.0023685-Guet1]. To simplify such types of constructions an idempotent cloning system has recently been developed by Tom Knight [@pone.0023685-Knight1] (described in the BioBrick Foundation Request for Comments \#10, BBF RFC 10; <http://biobricks.org/>). Briefly, this system uses a specific set of restriction enzyme sites at the 3′ and 5′ ends of each DNA cassette ('biobrick'), such that a biobrick 'A' may be fused with a biobrick 'B' to produce 'AB'. 'AB' contains an uncleavable 'scar' sequence between 'A' and 'B' and, importantly, the exact same set of restriction enzyme sites as the initial biobricks, at the 3′ and 5′ ends. In other words, every biobrick fusion product is itself a new biobrick and may even be used iteratively for the assembly of concatemers (See [Figure 1](#pone-0023685-g001){ref-type="fig"}). Given the physical idempotent characteristics of the system, biobricks may be fused together in any combination of parts, with few restrictions in the number of the biobricks, and no restrictions on the order ('BA' would be as simple to construct as 'AB').

![The biobrick assembly principle[@pone.0023685-Knight1], [@pone.0023685-Phillips1].\
(A) Each biobrick part has the same prefix and suffix, containing restriction enzyme sites. (B) Following restriction digests, a two-insert ligation into the biobrick vector results in a biobrick fusion. (C) The new biobrick part regenerates the original prefix and suffix, but contains an in-frame Thr-Arg scar in protein-coding fusions. (D) MS2 binding site concatemers (MS2 BS), built with iterative biobrick assembly, from 1 to 12-copies (4 steps). M = marker (1 kb ladder). The upstream and downstream sequences between the primer annealing sites and the biobricks contribute 312 bp, while each MS2 BS is 39 bp.](pone.0023685.g001){#pone-0023685-g001}

The RFC 10 Biobrick format [@pone.0023685-Knight1] is itself very useful and has formed the core of engineering challenges such as the annual International Genetically Engineered Machine (iGEM) competitions [@pone.0023685-Goodman1], where students are asked to engineer systems using biobricks. It is a well-documented system with a large and growing collection of parts that use the prefix GAATTCGCGGCCGCTTCTAGAG (or GAATTCGCGGCCGCTTCTAG for protein coding parts starting with ATG) and the suffix TACTAGTAGCGGCCGCTGCAG. However, the original scheme has certain limitations, such as the difficulty of fusing parts coding for protein domains, since the fusion 'scar' changes the codon reading frame from biobrick 'A' to biobrick 'B'. Phillips and Silver [@pone.0023685-Phillips1] resolved this issue by presenting a slight modification to the initial design (removing the last G of the prefix and the first T of the suffix thereby conserving the reading frame in the scar). Special attention is required when preparing new parts in this format (BBF RFC 23), since the removal of the last G of the prefix means that a Dam methylation site may be formed if the part starts with TC, which blocks restriction with Xba I. Since the scar resulting from a RFC 23 fusion (ACTAGA) codes for threonine-arginine, a chimeric protein 'AB' may be assembled from two RFC 23 biobricks 'A' and B'. When preparing such RFC 23 protein fusions, users should be aware that the arginine from the scar may be problematic since it is positively charged.

It is of interest to note that biobricks in the RFC 23 format may still be assembled with biobricks in the RFC 10 format without requiring new restriction enzymes. Although such a RFC 23-RFC 10 cross-fusion does not maintain the 6-bp scar required for the maintenance of a codon frame, N-terminal fusions of RFC 23 protein coding parts may still be performed as long as the frameshift is corrected by an adaptor part. In addition, the RFC 23-RFC 10 cross-fusion may be useful for assemblies that do not require the maintenance of a reading frame or a specific scar size, such as linking non-coding biobricks (e.g. transcription factor binding sites). We refer to this compatibility between RFC 23 and RFC 10 as 'assembly compatibility', that should not be confused with 'RFC 23 compatibility' that is reserved for fusion between biobricks that maintain the reading frame. Further biobrick formats (with only limited cross-compability) were later proposed and are documented as BBF RFCs.

Engineering with the Biobrick system is usually accompanied with an abstraction hierarchy perspective. With this perspective in mind, one uses 'DNA' to design basic 'parts' that may then be assembled into a single functional 'device' with a specific function. Finally, several of these 'devices' may be put together to design a synthetic 'system' with a high-level functionality. This hierarchy facilitates synthetic engineering since, ideally, a researcher working, for instance, at the 'system' level does not need to know the specific details on how to engineer and build the 'devices' used in that 'system'.

Synthetic biologists are now in the process of developing and characterizing basic 'parts' or part sets ('devices' [@pone.0023685-Canton1]) that may be used to engineer biological machines [@pone.0023685-Kelly1], [@pone.0023685-Rouilly1], [@pone.0023685-Grunberg1] and to model them [@pone.0023685-Weeding1]. These parts are available from the Registry of Standard Biological Parts (<http://partsregistry.org/>) which is supported by the BioBricks Foundation (<http://bbf.openwetware.org/>).

Although the registry is available to any researcher, whether or not they work in the field of synthetic biology, we believe that the size of the registry, the existence of different biobrick formats (not always compatible with each other), and the limited communication of this resource to non-synthetic biologists, may hamper the evolution and distribution of biobricks. We therefore developed a cloning tool that should be of interest outside the field of synthetic biology; a biobrick toolkit for the construction of custom eukaryotic expression plasmids, using frequently-used components. We originally noted that many biobrick parts that one would require for eukaryotic projects were apparently missing from the registry. These parts included: several multiple cloning sites with different reading frames; an extensive range of reporter proteins; eukaryotic selection markers; eukaryotic internal ribosomal entry sites; and protein epitope tags. Importantly, most of these parts should be compatible with each other [@pone.0023685-Phillips1], [@pone.0023685-Anderson1]. In addition, the novel use of MCS biobricks facilitates the cloning of DNA fragments of interest (e.g. open reading frames, promoters), without having to first remove any internal cleavage sites of the biobrick enzymes in order to render them 'biobrick compatible'.

This work is intended to highlight the potential of the biobrick system to construct custom plasmids for eukaryotic cell lines, for both synthetic and non-synthetic biologists. Since many parts that we consider important did not exist in the registry, we have built a distribution of 9 previously existing and 43 new biobricks. We demonstrate the utility of the new biobricks with some examples of assemblies. In addition, we use the created library to establish a gene-switching system, from tdTomato to EGFP expression, using recombinase-mediated DNA insertion (RMDI). Finally, we propose that this collection be distributed peer-to-peer as an independent library, as well as being available from the registry, and discuss some advantages in having this type of collection.

Materials and Methods {#s2}
=====================

Preparation of parts {#s2a}
--------------------

New parts were designed following the recommendations in BBF RFC 23. Briefly, parts were formatted to contain the prefix 5′-GAATTCGCGGCCGCTTCTAGA-3′ and the suffix 5′-ACTAGTAGCGGCCGCTGCAG-3′. Construction of the parts was done using 1) oligonucleotide inserts, 2) PCR with oligonucleotide-directed mutagenesis when required [@pone.0023685-Sambrook1] or 3) synthesized directly by GenScript Corporation (Piscataway, NJ). Importantly, the part sequences do not start with a TC since this forms a Dam methylase site (GATC) and digestion with XbaI can be inhibited. The Biobrick sequences are available at the Registry of Standard Biological Parts website (<http://partsregistry.org/>), at GenBank (<http://www.ncbi.nlm.nih.gov/genbank/>) and in the [Supporting Information S1](#pone.0023685.s001){ref-type="supplementary-material"}.

Biobrick assemblies {#s2b}
-------------------

Assemblies were performed similarly to the method presented in the Biobrick assembly kit from New England Biolabs (NEB; Ref. E0546S) and the Gingko Bioworks manual (<http://ginkgobioworks.com/support/>). Alternatively, one may use the adapted streamlined protocol we have previously reported [@pone.0023685-Grunberg1].

Briefly, 500 ng of the upstream part are digested with 20000 U of EcoRI (NEB) and 10000 U of SpeI (NEB) in NEB EcoRI buffer. At the same time, 500 ng of the downstream part are digested with 20000 U of XbaI (NEB) and 20000 U of PstI (NEB) in NEB Buffer 3. Finally and concomitantly, 500 ng of the destination plasmid are digested with 20000 U of EcoRI and 20000 U of PstI in NEB EcoRI Buffer. Digestions are performed at 37°C for 1 hour followed by heat inactivation at 80°C for 20 minutes. Note that the recipient pSB1A\* plasmids in the library contain a *ccdB* death cassette that is removed in the digestion. Furthermore, each assembly should contain an antibiotic resistance gene that is not present in either the upstream or the downstream part (e.g. if the upstream part is in the pSB1AK3 plasmid, containing ampicillin and kanamycin resistance, and the downstream part is in the pSB1AC3 plasmid, containing ampicillin and chloramphenicol resistance, the destination plasmid should be the pSB1AT3 plasmid since it contains the tetracycline resistance not present in the other plasmids).

Since the destination plasmid contains the *ccdB* death cassette, a two-way ligation of the fragments can be done using the Roche rapid DNA ligation kit, according to the manufacturer\'s instructions, without need for gel isolation or other purifications. Briefly, 4 µl of the upstream part digestion, 4 µl of the downstream part digestion and 2 µl of the destination plasmid digestion are used. 2 µl of the ligation product are transformed in one shot competent Top10 *E. coli* (Invitrogen), according to the manufacturer\'s instructions, and are subsequently plated onto LB agar plates. The plates contain antibiotic for the resistance provided by the destination plasmid (in the example above one should use LB agar plates containing tetracycline) and are incubated overnight.

PCRs of Biobricks (from plasmid DNA or bacterial colony) were performed using NEB Taq polymerase, using the manufacturer\'s instructions, and using the standard sequencing primers BBa_G00100 (5′-TGCCACCTGACGTCTAAGAA-3′) and BBa_G00101 (5′-ATTACCGCCTTTGAGTGAGC-3′) with 20 cycles at 55°C annealing temperature, with appropriate denaturation and elongation steps. PCR products were analyzed on agarose gels and positive colonies were grown overnight for DNA isolation using the Qiagen spin miniprep kit according to the manufacturer\'s instructions. All clones were verified by DNA sequencing.

Cell culture and transfection {#s2c}
-----------------------------

HEK293 cells were purchased from ATCC. Cells were propagated in Dulbecco\'s Modified Eagle Medium (Gibco) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin (Gibco). Transfection of the cells was performed with lipofectamine 2000 (Invitrogen), according to the manufacturer\'s instructions, in 6-well plates: cells were incubated for 4 hours with 4 µg of DNA and 10 µl of lipofectamine reagent. Stable clones were prepared by selection with 0.5 mg/ml G418 (Sigma).

Cloning small Espin into the MCS of a custom-made plasmid {#s2d}
---------------------------------------------------------

Rat small Espin (sEspin) [@pone.0023685-Bartles1] was amplified by PCR, from a plasmid kindly provided by the group of Hernán López-Schier, using the primers sEspinF (5′-AAGAGGGATCCATGAACTCCC-3′) and sEspinR (5′-CTTCTTACCGGTTTACTTAGGGATCTCCCCCTTC-3′) at 55°C annealing temperature. The PCR product was cloned into the Biobrick custom plasmid using the restriction enzymes BamHI and AgeI.

Microscopy {#s2e}
----------

After transfection, cells were allowed to recover overnight and were dispensed into glass bottom culture dishes (MatTek). 24 h later, the medium was replaced with PBS for observation under the microscope.

Recombinase-mediated DNA inclusion plasmid preparation {#s2f}
------------------------------------------------------

The plasmid used for the creation of the stable clone expressing tdTomato was prepared using an assembly of the biobricks between the CMV promoter and polyadenylation (pA) signal. The assembled plasmid was digested with XbaI and PstI and cloned into pEGFP-C1 digested with NheI and PstI, thereby removing the EGFP sequence and providing the CMV upstream and pA downstream of the biobrick insert. Neomycin resistance used for selection is provided by the pEGFP-C1 plasmid backbone under the expression of the SV40 early promoter. The EGFP plasmid for inclusion was prepared using the biobrick collection.

Flow cytometry {#s2g}
--------------

Flow-assisted cell sorting (FACS) analysis was performed with FACSCanto (BD) and cell separation with FACSARIA II (BD).

Results {#s3}
=======

Library {#s3a}
-------

To create a distribution for the construction of custom plasmids, we have put together a set of 9 existing and 43 new biobricks and plasmid backbones. We believe that these should be useful for the creation of custom-made plasmids for use in eukaryotic cell lines (see [Table 1](#pone-0023685-t001){ref-type="table"}). Importantly, a set of multiple cloning site (MCS) biobricks, covering all three different frames has been built, essential for the combination of the biobrick assembly strategy with classical cloning strategies ([Fig. 2](#pone-0023685-g002){ref-type="fig"}).

![Multiple Cloning Site (MCS) biobricks.\
The uniqueness of each cloning site is dependent on whether the remaining biobricks and backbones used for the custom plasmid also contain the restriction site. Blunt end restriction enzymes are represented in italic. These biobricks link classical cloning to the biobrick system.](pone.0023685.g002){#pone-0023685-g002}
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###### List of biobrick parts for eukaryotic plasmids.

![](pone.0023685.t001){#pone-0023685-t001-1}

  Group               Nickname                                                Description                                              Registry     GenBank
  --------------- ---------------- ------------------------------------------------------------------------------------------------- ------------- ----------
  Backbones           pSB1A3\*                         High copy number plasmid carrying ampicillin resistance.                         pSB1A3     
                     pSB1AK3\*                  High copy number plasmid carrying ampicillin and kanamycin resistance.                  pSB1AK3    
                     pSB1AC3\*               High copy number plasmid carrying ampicillin and chloramphenicol resistance.               pSB1AC3    
                     pSB1AT3\*                 High copy number plasmid carrying ampicillin and tetracyclin resistance.                 pSB1AT3    
  Construction         Kozak                       Simple Kozak sequence protein head domain [@pone.0023685-Kozak1]                   BBa_J96000    JN204869
                        Stop                               Tail domain with stop codons in all three frames                           BBa_J96001    JN204870
                       CMV\*                                   Cytomegalovirus immediate-early promoter                               BBa_I712004  
                      SV40pA\*                       Eukaryotic -- derived from SV40 early poly A signal sequence                     BBa_J52016   
                       MCS1a                                 Multiple cloning site version 1, first frame                             BBa_J96002    JN204871
                       MCS1b                                 Multiple cloning site version 1, second frame                            BBa_J96003    JN204872
                       MCS1c                                 Multiple cloning site version 1, third frame                             BBa_J96004    JN204873
                       MCS2a                                 Multiple cloning site version 2, first frame                             BBa_J96005    JN204874
                       MCS2b                                 Multiple cloning site version 2, second frame                            BBa_J96006    JN204875
                       MCS2c                                 Multiple cloning site version 2, third frame                             BBa_J96007    JN204876
                       MCS3a                                 Multiple cloning site version 3, first frame                             BBa_J96008    JN204877
                       MCS3b                                 Multiple cloning site version 3, second frame                            BBa_J96009    JN204878
                       MCS3c                                 Multiple cloning site version 3, third frame                             BBa_J96010    JN204879
  Selection          FNeomycin                        Resistance to G418/neomycin gene [@pone.0023685-Sambrook1]                      BBa_J96011    JN204880
                     FPuromycin                         Resistance to puromycin gene [@pone.0023685-Sambrook1]                        BBa_J96012    JN204881
                       FHSTK          Herpes simplex thymidine kinase conferring toxicity to ganciclovir [@pone.0023685-Reardon1]     BBa_J96013    JN204882
  Reporters           tdTomato                        Engineered red fluorescent protein [@pone.0023685-Shaner1]                      BBa_J96029    JN204883
                        EGFP                          Engineered green fluorescent protein [@pone.0023685-Zhang1]                     BBa_J96031    JN204884
                      Cerulean                        Engineered cyan fluorescent protein [@pone.0023685-Rizzo1]                      BBa_J96032    JN204885
                       EBFP2                            Engineered blue fluorescent protein [@pone.0023685-Ai1]                       BBa_J96033    JN204886
                     mCherry\*                        Engineered red fluorescent protein [@pone.0023685-Shaner1]                      BBa_J63000   
                    RLuciferase                           Renilla luciferase gene [@pone.0023685-Karkhanis1]                          BBa_J96034    JN204887
  Tags                  Flag                                  FLAG affinity tag [@pone.0023685-Einhauer1]                             BBa_J96035    JN204888
                         HA                                     HA affinity tag [@pone.0023685-Field1]                                BBa_J96036    JN204889
                        His                                    His affinity tag [@pone.0023685-Hochuli1]                              BBa_J96037    JN204890
                      StrepII                                Strep II affinity tag [@pone.0023685-Skerra1]                            BBa_J96038    JN204891
  Localization           SP                  Membrane or secretion: IgK leader peptide with Kozak [@pone.0023685-McKeown1]            BBa_J96014    JN204892
                        TMD                           PDGF Receptor Transmembrane Domain [@pone.0023685-McKeown1]                     BBa_J96015    JN204893
                   Myristoylation                  Myristoylation signal sequence with Kozak [@pone.0023685-Boutin1]                  BBa_J96016    JN204894
                       NLS\*                        Nuclear Localization Signal from SV40 [@pone.0023685-Kalderon1]                   BBa_J63008   
  Recombination         Loxp                                     Lox p sequence [@pone.0023685-Sauer1]                                BBa_J96017    JN204895
                       Lox66                     Directional lox sequence compatible with lox71 [@pone.0023685-Araki1]                BBa_J96018    JN204896
                       Lox71                     Directional lox sequence compatible with lox66 [@pone.0023685-Araki1]                BBa_J96019    JN204897
  Cistron               IRES                            Internal ribosomal entry site [@pone.0023685-Ghattas1]                        BBa_J96040    JN204898
                        P2A                               Self cleaving 2A peptide [@pone.0023685-Szymczak1]                          BBa_J96041    JN204899
                        T2A                               Self cleaving 2A peptide [@pone.0023685-Szymczak1]                          BBa_J96042    JN204900
                        PS3               Short DNA sequence for ribosome recruitment (mini-IRES) [@pone.0023685-Venkatesan1]         BBa_J96043    JN204901
                        PS4               Short DNA sequence for ribosome recruitment (mini-IRES) [@pone.0023685-Venkatesan1]         BBa_J96044    JN204902
  Others               Linker                                 24 aa flexible linker, rich in Gly and Ser.                             BBa_J96020    JN204903
                     Spacer1\*                                           Randomized DNA spacer                                        BBa_J96021   
                      Spacer2                                            Randomized DNA spacer                                        BBa_J96022    JN204904
                        MS2         MS2 phage coat domain binding to RNA at the MS2 binding site sequence [@pone.0023685-Valegard1]   BBa_J96023    JN204905
                       MS2BS                        MS2 phage coat binding site sequence [@pone.0023685-Valegard1]                    BBa_J96024    JN204906
                      LambdaN          Lambda N peptide sequence binding to RNA at the boxB binding site [@pone.0023685-Cilley1]      BBa_J96025    JN204907
                        BoxB                        Lambda N peptide binding site sequence [@pone.0023685-Cilley1]                    BBa_J96026    JN204908
                      TEVSite                    TEV tobacco etch virus protease cleavage site [@pone.0023685-Kapust1]                BBa_J96027    JN204909
                       d1PEST              Mouse ornithine decarboxylase PEST sequence 1 hr half-life [@pone.0023685-Zhao1]            BBa_96046    JN204910
                       d2PEST              Mouse ornithine decarboxylase PEST sequence 2 hr half-life [@pone.0023685-Zhao1]            BBa_96047    JN204911

Asterisks (\*) indicate previously existing Biobricks. "Registry" refers to the Registry reference, whereas "GenBank" refers to the GenBank accession number.

To facilitate flexible construction of custom-made plasmids, all biobricks are in the same format, containing the same prefix and suffix, as described in the Methods section. Biobricks may be divided into: (i) Non-coding (not intended for containing coding sequences; lengths are often not in multiples of three, or have a stop codons in the sequence). (ii) Head domains (that contain a Kozak sequence and are used to start the translation of the protein of interest). (iii) Internal domains (the coding regions for the desired domains (e.g. reporter proteins). (iv) Tail domains (containing the stop codon used to stop the translation of the protein of interest). (v) Translation units (containing the Kozak sequence, an internal domain and a stop codon). [Table 2](#pone-0023685-t002){ref-type="table"} indicates whether a given biobrick maintains the codon frame, whether it contains a Kozak sequence or a stop codon, and shows the restriction sites present in each biobrick or plasmid backbone. In this table we explicitly present those elements that may not be used for biofusion assembly (highlighted in bold).

10.1371/journal.pone.0023685.t002

###### Characteristics of the collection plasmids.

![](pone.0023685.t002){#pone-0023685-t002-2}

                        Name                  Restriction Sites              Kozak    Stop     Backbone   Size(bp)   3n    Well
  --------------- ---------------- ---------------------------------------- ------- --------- ---------- ---------- ----- ------
  Backbones          **pSB1A3**                                               \-       \-         \-       2157\*    \-     1A
                    **pSB1AK3**           ClaI, HindIII, SmaI, XhoI           \-       \-         \-       3189\*    \-     1B
                    **pSB1AC3**                   SacI, XhoI                  \-       \-         \-       3055\*    \-     1C
                    **pSB1AT3**     BamHI, ClaI, HindIII, SalI, SphI, XhoI    \-       \-         \-       3446\*    \-     1D
  Construction         Kozak                                                  YES       N         AK         12      YES    1E
                      **Stop**                                                 N     **YES**      AK         11       N     1F
                      **CMV**                        SacI                      N     **YES**      AK        654      YES    1G
                     **SV40pA**                      SphI                      N     **YES**      AK        228      YES    1H
                     **MCS1a**            ApaI, XhoI, BamHI, HindIII           N        N         AK         32       N     2A
                       MCS1b              ApaI, XhoI, BamHI, HindIII           N        N         AT         33      YES    2B
                     **MCS1c**            ApaI, XhoI, BamHI, HindIII           N        N         AT         34       N     2C
                       MCS2a               BglII, SacI, KpnI, AgeI             N        N         AT         30      YES    2D
                     **MCS2b**             BglII, SacI, KpnI, AgeI             N        N         AT         31       N     2E
                     **MCS2c**             BglII, SacI, KpnI, AgeI             N        N         AT         32       N     2F
                       MCS3a            BsrGI, StuI, SalI, SphI, ClaI          N        N         AC         39      YES    2G
                     **MCS3b**          BsrGI, StuI, SalI, SphI, ClaI          N        N         AC         40       N     2H
                     **MCS3c**          BsrGI, StuI, SalI, SphI, ClaI          N       YES        AC         41       N     3A
  Selection        **FNeomycin**                     SphI                     YES    **YES**      AK        801      YES    4A
                   **FPuromycin**                    StuI                     YES    **YES**      AC        606      YES    4B
                     **FHSTK**                 ApaI, SmaI, SphI               YES    **YES**      AC        1137     YES    4C
  Reporters           tdTomato                                                 N        N         AK        1425     YES    5A
                        EGFP                        BsrGI                      N        N         AC        714      YES    5B
                     mCerulean                   BsrGI, ClaI                   N        N         AC        714      YES    5C
                       EBFP2                                                   N        N         AC        714      YES    5D
                      mCherry                                                  N        N         A         705      YES    5E
                    RLuciferase                  BsrGI, SphI                   N        N         AK        930      YES    5F
  Tags                  Flag                                                   N        N         AC         24      YES    6A
                         HA                                                    N        N         AC         27      YES    6B
                        His                                                    N        N         AC         18      YES    6C
                      StrepII                                                  N        N         AC         24      YES    6D
  Localization           SP                                                   YES       N         AC         69      YES    7A
                        TMD                                                    N        N         AC        147      YES    7B
                       Myrist                                                 YES       N         AC         48      YES    7C
                        NLS                                                    N        N         A          21      YES    7D
  Recombination         Loxp                                                   N        N         AC         36      YES    8A
                       Lox66                                                   N        N         AC         36      YES    8B
                       Lox71                                                   N        N         AC         36      YES    8C
  Cistron             **IRES**               ApaI, HindIII, KpnI               N     **YES**      AC        504      YES    9A
                        P2A                          SmaI                      N        N         AC         42      YES    9B
                        T2A                                                    N        N         AC         54      YES    9C
                      **PS3**                       BsrGI                      N     **YES**      AC         50       N     9D
                      **PS4**                                                  N     **YES**      AC         48      YES    9E
  Others               Linker                                                  N        N         AC         72      YES   10A
                    **Spacer1**                                                N     **YES**      A          72      YES   10B
                    **Spacer2**                                                N        N         AK         70       N    10C
                        MS2                   BglII, SacI, SalI                N        N         AK        387      YES   10D
                       MS2BS                         SalI                      N        N         AC         39      YES   10E
                      LambdaN                                                  N        N         AC         66      YES   10F
                        BoxB                         ApaI                      N        N         AC         21      YES   10G
                      TEVSite                                                  N        N         AC         21      YES   10H
                     **d1PEST**                                                N     **YES**      AT        129      YES   11A
                     **d2PEST**                                                N     **YES**      AT        129      YES   11B

Characteristics of the collection plasmids. In bold we present all plasmids that, when fused, do not allow for a continuous coding sequence (either because they contain a stop signal or because the length in bp is not a multiple of 3: "3n"). A (ampicillin), C (chloramphenicol), K (kanamycin) and T (tetracycline) indicate the resistances provided by each backbone. The position of samples in the distribution is indicated by "Well". Asterisks (\*) indicate that the presented size refers to the plasmid size instead of the biobrick size.

Whereas the biobrick assembly workflow will work for all parts in the collection, for classical cloning it is up to the user to check which biobricks will be used to assemble a plasmid. For example, the user must check whether a given restriction enzyme site is present only once (e.g. in the MCS site region) or whether it is not unique and is also found in another biobrick or plasmid backbone.

Constructing simple assemblies {#s3b}
------------------------------

The biobrick assembly principle is inherently iterative, allowing longer and longer poly-biobrick constructs to be built in a stepwise fashion ([Fig. 1](#pone-0023685-g001){ref-type="fig"}). This is particularly useful for making related constructs with variable copies of a motif, such as a transcription factor binding sites. To illustrate this, we show how the binding sites of the bacterial MS2 phage coat protein, which can be used to repress mRNA translation in synthetic biology applications [@pone.0023685-Isaacs1], can be conveniently concatenated with biobrick assembly ([Fig. 1D](#pone-0023685-g001){ref-type="fig"}).

One of the simplest expression plasmids that one might construct using the distribution is a plasmid such as that presented in [Figure 3A](#pone-0023685-g003){ref-type="fig"}; a simple EGFP expression plasmid, used to label cells, as may be observed in [Figure 3B](#pone-0023685-g003){ref-type="fig"}. A user will typically want to create a translation unit and insert it under a promoter with a polyadenylation sequence in the end. The translation unit will typically be composed of a head domain (in this case the Kozak sequence alone) followed by one or more internal domains (in this example the EGFP reporter coding sequence) and finished with a tail domain (here the simple stop codon biobrick).

![Examples of biobrick assemblies.\
(A) Structure of a classical plasmid for EGFP expression using 5 biobricks. (B) Structure of bicistronic custom plasmid. 8 biobricks are linked together to make a construct for C-terminal fusions to the blue fluorescent protein, cerulean, using classical restriction enzyme multiple cloning sites (MCS). For illustration, the actin-bundling binding protein sEspin is cloned into the MCS, resulting in a fusion with cerulean. (C) Fluorescence microscopy image of the EGFP construct in panel A, after transient transfection into HEK293 cells. (D) A fluorescence microscopy image of the Cerulean-sEspin fusion construct in panel B, allows the visualisation of stress fiber-like structures in a HEK293T cell. Scale bars are indicated below each image.](pone.0023685.g003){#pone-0023685-g003}

Constructing a MCS plasmid for classical cloning {#s3c}
------------------------------------------------

Although many commercially-available plasmids contain MCSs to allow fusing proteins of interest to fluorescent proteins, many combinations of colours, N-C orientations, stable cell-line selection genes or half-life modifications are simply not available. To illustrate this we have created a more complex plasmid, containing two cistrons, that is not commercially-available. In the first cistron, we assembled the blue fluorescent protein cerulean [@pone.0023685-Rizzo1] before a complex MCS (assembled using MCS1 and MCS2). We subsequently cloned an actin-binding protein, rat sEspin [@pone.0023685-Bartles1], using the BamHI and AgeI restriction sites ([Figure 3C](#pone-0023685-g003){ref-type="fig"}). By fluorescent microscopy, we observed Cerulean-sEspin localization in actin bundle stress fiber-like structures [@pone.0023685-Bartles1] ([Fig. 3D](#pone-0023685-g003){ref-type="fig"}). In the second cistron we included the neomycin resistance gene for positive selection. The example shown is just one of many customized cloning vectors that can be generated with this platform, and requires just three biobrick cloning iterations (first round: CMV-Kozak, Cerulean-MCS1a, MCS2a-IRES, Neomycin-pA; second round: CMV-Kozak-Cerulean-MCS1a, MCS2a-IRES-Neomycin-pA; third round: CMV-Kozak-Cerulean-MCS1a-MCS2a-IRES-Neomycin-pA). The use of MCSs links the biobrick format to classical cloning strategies, which should increase their appeal to researchers who simply wish to 'cut and paste' their DNA cassettes with standard restriction enzymes.

Recombinase-Mediated DNA Insertion {#s3d}
----------------------------------

The collection presented here may be used to obtain stable cloning systems, for chromosomal integration in eukaryotic cells, such as Recombinase-Mediated DNA Insertion (RMDI) [@pone.0023685-Fukushige1]. We implemented RMDI by establishing a stable cell line expressing tdTomato, and containing an heteromeric lox site in its coding sequence (lox66 [@pone.0023685-Albert1]; see scheme in [Figure 4A](#pone-0023685-g004){ref-type="fig"}). Through Cre-mediated recombination we inserted DNA from a donor plasmid, containing EGFP preceded by a compatible heteromeric site (lox71). Thus, red expression was converted to green expression.

![Recombinase-mediated DNA insertion with biobricks.\
(A) Schematic view of Cre-mediated recombination between lox66 and lox71, resulting in the insertion of EGFP and creating a mutated lox site (loxM) and a loxP site. This prevents the original tdTomato from being expressed while allowing EGFP expression. (B, C and D) Flow cytometry analysis of a stable cell line expressing tdTomato, with various recombinase or cell sorting treatments. (B) The untreated cell line (−Cre) contains mainly red-positive cells (72%). (C) Upon recombinase treatment (+Cre), the amount of green cells increases in quadrants 2 and 4 (Q2, Q4). (D) By sorting the green cells (Q2 and Q4 in the previous panel), using flow cytometry (+Sort), and growing to confluency, the resulting cells are enriched for the newly-generated green cells (20%; Q4).](pone.0023685.g004){#pone-0023685-g004}

Since the EGFP plasmid did not contain a promoter, cells should express EGFP alone only if inserted at the correct RMDI site. Expression from random insertions next to genomic promoters (expected to be rare events) would be associated with both green and red expression. However, in the early stages after transfection, even correctly recombined cells would be expected to have some residual red expression, until the levels of tdTomato were degraded or diluted by cell division.

Indeed, after three days we observed a cell population expressing both EGFP and tdTomato by flow cytometry (0.23% for RMDI when using both the EGFP plasmid and Cre versus 0.08% for random insertion in the control with the EGFP plasmid without Cre; [Fig. 4B and C](#pone-0023685-g004){ref-type="fig"}). Thus, there appeared to be some Cre-induced increase in GFP fluorescence, but it was not clear whether the effects were site-specific or due to background fluorescence. Therefore, to investigate whether the tdTomato levels would subsequently fall, indicating correct RMDI, we sorted the EGFP-positive population in [Figure 4C](#pone-0023685-g004){ref-type="fig"}, grew them to confluency and re-analysed the final population. We thus obtained a population of cells where RMDI had indeed occurred, with high levels of EGFP and low levels of tdTomato, similar to non-fluorescent controls (20% green-only cells; [Fig. 4D](#pone-0023685-g004){ref-type="fig"}).

When considering only the EGFP-positive population (Q2+Q4) we note a marked shift in the Q4 population (8% of Q2+Q4 before sorting to 83% of Q2+Q4 after sorting and regrowth). This suggests that the insertion of the EGFP plasmid occurred at the intended lox site, thereby disrupting tdTomato, but that extra time was required for tdTomato levels to fall, via dilution and degradation, during regrowth of the sorted cells.

The 17% of Q2+Q4 found in Q2 is an EGFP-tdTomato double-positive population (4% of the total cell population; [Fig. 4D](#pone-0023685-g004){ref-type="fig"}), likely arising from cells containing multiple chromosomal copies of the initial tdTomato construct: here recombination occurred in one or more instances, but not in every copy. Random integrations of GFP near promoter regions are likely to be rare but may also contribute to this population.

We also observed tdTomato-positive EGFP-negative (32%) and tdTomato-EGFP double-negative (45%) populations. These are likely arising from cells that were unmodified and yet were carried-through the EGFP cell sorting step (false positives) or from cells that downregulated the CMV promoter [@pone.0023685-Migliaccio1].

Discussion {#s4}
==========

In this work, we have created a distribution of DNA fragments compatible with the Standard Registry of Biological Parts [@pone.0023685-Knight1]. This distribution is intended for the specific use of creating custom-made plasmids, with a focus on use in eukaryotic cell lines, particularly because many previous parts have focused on prokaryotic components. We have therefore constructed biobricks for elements that are routinely used in plasmids for transfection in eukaryotic cell lines. Using these elements, we provide three examples of applications of this system: the assembly of sequence motif concatemers; the assembly of vectors for transient and stable transfection; and a Cre-based Recombinase-Mediated DNA Insertion.

Although the present work makes use of existing concepts, such as the standardization of DNA parts [@pone.0023685-Arkin1] and classical cloning for expression in eukaryotic cell lines [@pone.0023685-Sambrook1], the construction of the required elements into one collection and the combination of both cloning concepts makes this method a distinct new resource for preparing eukaryotic contructs. To provide this tool to users, we propose that the collection presented here be available as a stand-alone biobrick distribution exchanged in a peer-to-peer fashion, in addition to its availability through the Registry of Standard Biological Parts (<http://partsregistry.org/>).

A researcher may request access to the Registry to obtain a large collection of biobricks which are a valuable resource, especially to synthetic biologists. However, the size of the Registry database may be detrimental in some instances, especially for sporadic users. One example of this is the impossibility - at the moment - to search the registry database for biobricks in a specific format. In fact, special care must be taken when using biobricks from the registry since it is not always clear whether two internal protein domain biobricks may be fused in frame, because of the different biobrick formats [@pone.0023685-Phillips1], [@pone.0023685-Anderson1]. This is in part due to the definition of the registry database of biobricks as being 'compatible' with a given format when meaning they may be assembled together even if the coding frame is not maintained, whereas other users may consider 'compatibility' as an indication that the fusion conserves the codon frame.

In contrast, RFC 23 compatibility in the small collection presented here -- in the sense of codon reading frame conservation -- is ensured except where otherwise explicitly stated. Another advantage of having an independent small distribution for a specific function is the possibility to exchange it in 96-well plates and to be sure that one is using sequence-verified components. For example, when sequence-verifying the registry, certain discrepancies have been found [@pone.0023685-Peccoud1]. The bacteria containing the plasmids can be grown and shipped in wells filled with agar medium, allowing direct sharing between peers, without need for advanced robotics or pipetting systems.

We believe that other similar biobrick libraries should be created to be self-contained. That is, all parts in such libraries should be compatible and sufficient to be used for a specific function. For instance one could envisage kinase-phosphatase or signalling cascade libraries; transcription factor libraries; metabolic enzyme libraries. Such a library-based form of distribution may be one of several solutions for the growing size of the Registry that may rapidly reach a limit in the cost-efficiency of its own distribution (the registry is \>13 000 parts and growing [@pone.0023685-Galdzicki1]). Ultimately, we hope to stimulate debate in this growing open standard for biological engineering.

Supporting Information {#s5}
======================

###### 

**FASTA DNA sequences of the Biobrick Collection.** Prefix and Suffix are presented in capitals.

(DOC)

###### 

Click here for additional data file.
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